Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia

NCT04878055 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT04878055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04878055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2021
Completion date
October 31, 2021
Enrollment
287 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pneumonia, viral